Ursula A Matulonis

Ursula A Matulonis

UNVERIFIED PROFILE

Are you Ursula A Matulonis?   Register this Author

Register author
Ursula A Matulonis

Ursula A Matulonis

Publications by authors named "Ursula A Matulonis"

Are you Ursula A Matulonis?   Register this Author

100Publications

3727Reads

28Profile Views

Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.

Gynecol Oncol 2020 Feb 17;156(2):488-497. Epub 2019 Oct 17.

Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.09.021DOI Listing
February 2020

Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.

Am J Obstet Gynecol 2019 Dec 14;221(6):625.e1-625.e14. Epub 2019 Jun 14.

Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA; Division of Gynecologic Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajog.2019.06.009DOI Listing
December 2019

Prediagnosis and postdiagnosis smoking and survival following diagnosis with ovarian cancer.

Int J Cancer 2019 Nov 6. Epub 2019 Nov 6.

Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32773DOI Listing
November 2019

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.

N Engl J Med 2019 06;380(24):2317-2326

From Northwestern University (D. Matei) and Loyola University (W.S.) - both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island-The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph's-Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana-Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1813181DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948006PMC
June 2019

Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).

Int J Gynecol Pathol 2019 May;38(3):230-240

Department of Pathology, Women's and Perinatal Pathology Division (H.M.D., K.C.S., E.E.M., W.R.W., M.S.H., B.J.Q., K.R.L., C.P.C., G.L.M., M.R.N., B.E.H.) Division of Gynecologic Oncology and Reproductive Biology (M.G.M., J.F.L., C.F., N.H., R.S.B.), Brigham and Women's Hospital Department of Pathology, Beth Israel Deaconess Medical Center (M.G., J.L.H., D.I.L.) Medical Gynecologic Oncology Program, Dana-Farber Cancer Institute (E.S., P.A.K., U.A.M.), Harvard Medical School, Boston, Massachusetts Department of Pathology, Duke University Medical Center, Durham, North Carolina (K.C.S.) Department of Gynecology and Obstetrics, Odense University Hospital, University of Southern Denmark, Odense, Denmark (K.M.J.) Department of Pathology, Stanford University, Stanford, California (B.E.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000513DOI Listing
May 2019

-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure.

Gynecol Oncol Rep 2019 May 29;28:15-17. Epub 2019 Jan 29.

Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23525789193001
Publisher Site
http://dx.doi.org/10.1016/j.gore.2019.01.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357694PMC
May 2019

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Lancet Oncol 2019 May 1;20(5):636-648. Epub 2019 Apr 1.

Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St Joseph's Hospital, Phoenix, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30029-4DOI Listing
May 2019

Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer.

Hematol Oncol Clin North Am 2018 12;32(6):997-1010

Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08898588183075
Publisher Site
http://dx.doi.org/10.1016/j.hoc.2018.07.006DOI Listing
December 2018

Ovarian Cancer.

Hematol Oncol Clin North Am 2018 12 25;32(6):xiii-xiv. Epub 2018 Sep 25.

Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08898588183079
Publisher Site
http://dx.doi.org/10.1016/j.hoc.2018.09.006DOI Listing
December 2018

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.

Cell Rep 2018 12;25(11):2972-2980.e5

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22111247183181
Publisher Site
http://dx.doi.org/10.1016/j.celrep.2018.11.054DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366450PMC
December 2018

Targeted Next-Generation Sequencing Reveals Clinically Actionable and Mutations in Low-Grade Serous Ovarian Carcinoma.

JCO Precis Oncol 2018 8;2018. Epub 2018 Nov 8.

Elizabeth H. Stover, Ursula A. Matulonis, and Panagiotis A. Konstantinopoulos, Dana-Farber Cancer Institute, Harvard Medical School; and Colleen Feltmate, Ross S. Berkowitz, and Neal I. Lindeman, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.18.00135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394870PMC
November 2018

PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.

Clin Cancer Res 2018 09 5;24(17):4062-4065. Epub 2018 Jun 5.

Division of Gynecologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1314DOI Listing
September 2018

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.

Gynecol Oncol 2018 08 22;150(2):219-226. Epub 2018 Jun 22.

Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.05.028DOI Listing
August 2018

Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study.

Lancet Oncol 2018 08 18;19(8):1107-1116. Epub 2018 Jul 18.

Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30373-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242286PMC
August 2018

BRAF and AXL oncogenes drive RIPK3 expression loss in cancer.

PLoS Biol 2018 08 29;16(8):e2005756. Epub 2018 Aug 29.

Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pbio.2005756DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114281PMC
August 2018

Management of newly diagnosed or recurrent ovarian cancer.

Clin Adv Hematol Oncol 2018 Jun;16(6):426-437

Harvard Medical School and Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
June 2018

The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.

Gynecol Oncol 2018 04 4;149(1):214-220. Epub 2018 Feb 4.

Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.01.011DOI Listing
April 2018

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.

Future Oncol 2018 Jan 3;14(2):123-136. Epub 2017 Nov 3.

Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0379DOI Listing
January 2018

Highlights in Ovarian Cancer From the 2017 American Society of Clinical Oncology Annual Meeting: Commentary.

Clin Adv Hematol Oncol 2017 Aug;15 Suppl 7(8):13-17

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
August 2017

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

J Clin Oncol 2017 Apr 28;35(10):1112-1118. Epub 2016 Dec 28.

Kathleen N. Moore, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Lainie P. Martin, Fox Chase Cancer Center, Philadelphia, PA; David M. O'Malley, Ohio State University James Cancer Center, Columbus, OH; Ursula A. Matulonis, Dana-Farber Cancer Institute; Michael J. Birrer, Massachusetts General Hospital, Boston; Rodrigo Ruiz-Soto, ImmunoGen, Waltham, MA; Jason A. Konner, Memorial Sloan Kettering Cancer Center, New York, NY; Raymond P. Perez, University of Kansas, Fairway, KS; and Todd M. Bauer, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.9538DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559878PMC
April 2017

Niraparib in Recurrent Ovarian Cancer.

N Engl J Med 2017 02;376(8):801-2

Dana–Farber Cancer Institute, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1616633DOI Listing
February 2017

Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.

Expert Opin Investig Drugs 2016 16;25(5):597-611. Epub 2016 Mar 16.

a Cancer Therapy Evaluation Program , National Cancer Institute , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2016.1156857DOI Listing
December 2016

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.

Clin Cancer Res 2016 Dec 27;22(23):5651-5660. Epub 2016 Sep 27.

University of Washington, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0247DOI Listing
December 2016

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

N Engl J Med 2016 12 7;375(22):2154-2164. Epub 2016 Oct 7.

From the Nordic Society of Gynecological Oncology and Rigshospitalet-Copenhagen University Hospital, Copenhagen (M.R.M.), Odense University Hospital (J.H.) and European Network for Gynacological Oncological Trial and Research Unit of General Practice, Institute of Public Health, University of Southern Denmark, Odense (R.D.C.) - all in Denmark; University of Arizona and Creighton University-Phoenix, Phoenix (B.J.M.), and Arizona Oncology Associates, Tuscon (B.J.M., J.B.) - all in Arizona; Princess Margaret Consortium, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (A.M.O.), British Columbia Cancer Agency, Vancouver (A.V.T.), and McGill University-McGill University Health Centre, Montreal (L.G.) - all in Canada; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and the University of Munich, Munich (S.M.), and Kliniken Essen Mitte, Essen (A.B.) - both in Germany; Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Hospital Universitario La Paz (A.R.), and GEICO and M.D. Anderson Cancer Center Madrid (A.G.-M.), Madrid; French Investigator Group for Ovarian and Breast Cancer (GINECO) and Institut du Cancer de Montpellier, Montpellier (M.F.), and GINECO and Centre Antoine Lacassagne, Nice (P.F.) - both in France; National Cancer Research Institute and UCL Cancer Institute, University College London, London (J.A.L.); Multicenter Italian Trials in Ovarian Cancer/Mario Negri Gynecologic Oncology Group, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan (D.L.); Belgium and Luxembourg Gynecological Oncology Group and University of Leuven, Leuven, Belgium (I.V.); Kaplan Medical Center, Rehovot, Israel (N.E.B.-B.); AGO-Austria and Medical University Innsbruck, Innsbruck, Austria (C.M.); Central and Eastern European Gynecologic Oncology Group and Uniwersytet Medyczny w Poznaniu, Poznan, Poland (R.M.); Stanford Comprehensive Cancer Institute, Stanford (J.S.B.), and Cedars-Sinai Medical Center, West Hollywood (B.J.R.) - both in California; Oslo University Hospital, Radiumhospitalet, Oslo (A.D.); Northside Hospital, Atlanta (B.B.); Universitetssjukhuset, Linköping, Sweden (P.R.); and Veristat, Southborough (J.P.B.), Tesaro, Waltham (S.A.), and Dana-Farber Cancer Institute, Boston (U.A.M.) - all in Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611310DOI Listing
December 2016

Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.

J Clin Oncol 2016 11;34(32):3854-3863

Larissa A. Meyer, Charlotte C. Sun, and Charles F. Levenback, The University of Texas MD Anderson Cancer Center, Houston, TX; Angel M. Cronin, Ursula A. Matulonis, and Alexi A. Wright, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA; Kristin Bixel and David M. O'Malley, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Michael A. Bookman, US Oncology Research and Arizona Oncology, Tucson, AZ; Mihaela C. Cristea and Joyce C. Niland, City of Hope Comprehensive Cancer Center, Duarte, CA; Jennifer J. Griggs, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Robert A. Burger, University of Pennsylvania; and Gina Mantia-Smaldone, Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.1239DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477982PMC
November 2016

Ovarian cancer.

Nat Rev Dis Primers 2016 08 25;2:16061. Epub 2016 Aug 25.

Women's Cancer Program, Cedars-Sinai Medical Center, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrdp.2016.61DOI Listing
August 2016

Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer.

Gynecol Oncol 2016 06 8;141(3):405-409. Epub 2016 Apr 8.

Cancer Treatment Centers of America, Philadelphia, PA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2016.03.005DOI Listing
June 2016

What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

Curr Oncol Rep 2016 May;18(5):29

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-016-0515-zDOI Listing
May 2016

Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions.

J Allergy Clin Immunol 2016 Apr 23;137(4):1154-1164.e12. Epub 2015 Dec 23.

Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Boston, Mass. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2015.10.039DOI Listing
April 2016

Precision medicine.

Gynecol Oncol 2016 Apr;141(1)

Gynecologic Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2016.03.017DOI Listing
April 2016

Genomic testing and precision medicine--What does this mean for gynecologic oncology?

Gynecol Oncol 2016 Jan 4;140(1):3-5. Epub 2015 Dec 4.

Gynecologic Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2015.12.001DOI Listing
January 2016

Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.

J Clin Oncol 2015 Sep 3;33(26):2841-7. Epub 2015 Aug 3.

Alexi A. Wright, Angel Cronin, Dana E. Milne, Nancy L. Keating, Ursula A. Matulonis, and Jane C. Weeks, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA; Michael A. Bookman, University of Arizona Cancer Center, Tucson, AZ; Robert A. Burger, University of Pennsylvania; Gina Mantia-Smaldone, Fox Chase Cancer Center, Philadelphia, PA; David E. Cohn and David M. O'Malley, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Mihaela Cristea and Joyce C. Niland, City of Hope Comprehensive Cancer Center, Duarte, CA; Jennifer J. Griggs, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and Charles F. Levenback and Larissa A. Meyer, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.4776DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554746PMC
September 2015

Bevacizumab in newly diagnosed ovarian cancer.

Lancet Oncol 2015 Aug 23;16(8):876-8. Epub 2015 Jun 23.

Gynecology Oncology Program, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00064-9DOI Listing
August 2015

Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials.

Cancer 2015 Jun 21;121(11):1737-46. Epub 2014 Oct 21.

UCL Cancer Institute, University College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29082DOI Listing
June 2015

POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: implications for Lynch syndrome testing.

Cancer 2015 Feb 15;121(3):331-4. Epub 2014 Sep 15.

Gynecologic Oncology Program, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29057DOI Listing
February 2015

Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer.

Clin Cancer Res 2015 Feb 18;21(4):808-18. Epub 2014 Dec 18.

Biological Sciences Platform, Sunnybrook Research Institute, Toronto, Ontario, Canada. Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2810DOI Listing
February 2015

A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.

Cancer Res 2015 Feb 29;75(4):628-34. Epub 2015 Jan 29.

Department of Medical Oncology, Medical Gynecologic Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-14-2593DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416405PMC
February 2015

New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances.

Clin Cancer Res 2014 Oct;20(20):5150-6

Gynecologic Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1312DOI Listing
October 2014

Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.

PLoS One 2013 12;8(11):e80023. Epub 2013 Nov 12.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America ; Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0080023PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827141PMC
July 2014

Hopelessness and complementary therapy use in patients with ovarian cancer.

Cancer Nurs 2013 Jul-Aug;36(4):256-64

Department of Nursing and Patient Care Services, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/NCC.0b013e31826f3bc4DOI Listing
May 2014

PARP inhibitors in ovarian cancer: current status and future promise.

Gynecol Oncol 2014 May 4;133(2):362-9. Epub 2014 Mar 4.

Gynecologic Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2014.02.039DOI Listing
May 2014

Chemotherapy hypersensitivity reactions in ovarian cancer.

J Natl Compr Canc Netw 2014 Mar;12(3):389-402

From the aDivision of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School and bDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0040DOI Listing
March 2014

Current status and evolution of preclinical drug development models of epithelial ovarian cancer.

Front Oncol 2013 Dec 11;3:296. Epub 2013 Dec 11.

Medical Gynecologic Oncology Program, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School , Boston, MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2013.00296DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858677PMC
December 2013

Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients.

Gynecol Oncol 2013 Nov 13;131(2):352-6. Epub 2013 Aug 13.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2013.08.006DOI Listing
November 2013

Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.

Cancer 2013 Nov 23;119(21):3776-83. Epub 2013 Aug 23.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Centers for Outcomes and Policy Research and Psychosocial Epidemiology and Outcomes Research, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28288DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972000PMC
November 2013

Ovarian cancer, version 2.2013.

J Natl Compr Canc Netw 2013 Oct;11(10):1199-209

From 1City of Hope Comprehensive Cancer Center; 2University of Alabama at Birmingham Comprehensive Cancer Center; 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 4Fox Chase Cancer Center; 5UCSF Helen Diller Family Comprehensive Cancer Center; 6he Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 7Vanderbilt-Ingram Cancer Center; 8The University of Texas MD Anderson Cancer Center; 9University of Washington/Seattle Cancer Care Alliance; 10Moffitt Cancer Center; 11Duke Cancer Institute; 12University of Michigan Comprehensive Cancer Center; 13Roswell Park Cancer Institute; 14Dana-Farber/Brigham and Women's Cancer Center; 15Massachusetts General Hospital Cancer Center; 16Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 17Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 18Memorial Sloan-Kettering Cancer Center; 19St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 20Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 21Stanford Cancer Institute; 22Huntsman Cancer Institute at the University of Utah; and 23National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2013.0142DOI Listing
October 2013

Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function.

J Psychosoc Oncol 2012 ;30(4):387-401

Harvard Medical School, Dana Farber Cancer Institute, Department of Gynecology Oncology, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07347332.2012.684854DOI Listing
September 2012

Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.

Gynecol Oncol 2012 Jul 6;126(1):41-6. Epub 2012 Apr 6.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2012.04.003DOI Listing
July 2012

Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.

Gynecol Oncol 2012 May 12;125(2):362-6. Epub 2012 Feb 12.

Brigham and Women's Hospital, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2012.02.006DOI Listing
May 2012

New biologic agents for the treatment of gynecologic cancers.

Hematol Oncol Clin North Am 2012 Feb;26(1):133-56

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2011.11.002DOI Listing
February 2012